How much did CytoDyn raise?

CytoDyn raised $882,000 in a Seed round on March 30, 2020.

Where is CytoDyn based and how big is it?

CytoDyn is based in Vancouver, Washington, United States. Fundz records about 21 employees.

Who are the decision-makers at CytoDyn?

Fundz holds 2 contacts at CytoDyn, including the Chief Financial Officer. Names and contact details are shown to Fundz members.

Cyto Dyn Inc. reported raising $882,000 in an initial SEC Form D filing, from an offering of $1.16 Million

PUBLIC · CYDYMar 30, 2020$882K of $1.2M raised

Amount Raised

$882,000

$882,000 sold, per SEC Form D (first sale Mar 30, 2020)

Round Type

Seed

VancouverBiotechnologyHealthcareHealth CareTherapeutics

Quick answer

CytoDyn raised $882,000 in a Seed round, dated March 30, 2020. CytoDyn is based in Vancouver, Washington, United States.

How much did CytoDyn raise?: CytoDyn raised $882,000 in a Seed round on March 30, 2020.
What does CytoDyn do?: CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV.
Where is CytoDyn based and how big is it?: CytoDyn is based in Vancouver, Washington, United States. Fundz records about 21 employees.
Who are the decision-makers at CytoDyn?: Fundz holds 2 contacts at CytoDyn, including the Chief Financial Officer. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as CytoDyn that raised within 45 days of this round, from Fundz verified event records.

Ocugen raised $395 (Pre-Seed) on May 7, 2020.
Ocugen raised $14M on May 7, 2020.
Os Therapies raised an undisclosed amount on May 1, 2020.
Phio Pharmaceuticals raised $4.4M on April 14, 2020.
Crispr Therapeutics raised $1M (Seed) on April 9, 2020.
Olema Pharmaceuticals, Inc. raised $30M on March 27, 2020.

Who to call at CytoDyn, and when

A new round usually means CytoDyn is about to hire and buy. The teams that reach out first get the meeting.

An alert the day CytoDyn raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at CytoDyn, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at CytoDyn. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

CytoDyn

Location

1111 Main Street

Vancouver, Washington, United States

About

CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in the liver, cells that undergo malignant transformation, and is the predominant co-receptor needed for certain strains of HIV to infect healthy T-cells. The CCR5 receptor serves as a receptor for chemical attractants called chemokines. Chemokines are the key orchestrators of leukocyte trafficking by attracting immune cells to the sites of inflammation.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment CytoDyn raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans

Related People

2 contacts

Verified contactsRobert H., Chief Financial Officer hiddenSee plans and pricing

Predictive Intelligence

Strategic

ML-powered predictions for CytoDyn's next move

See what Strategic adds

CytoDyn raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

Show me how a sales rep uses this Or see plans and pricing →

5 screens from a live account. No signup.